Breaking News Instant updates and real-time market news.

NKTR

Nektar

$15.50

-0.21 (-1.34%)

10:08
03/20/17
03/20
10:08
03/20/17
10:08

Nektar surges after success of opoid painkiller in Phase 3 study

Shares of Nektar Therapeutics (NKTR) surged in morning trading after the company said that a late-stage trial of NKTR-181, which was previously granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of moderate to severe chronic pain, met the primary and secondary endpoints. PHASE 3 STUDY RESULTS: Nektar Therapeutics announced this morning that NKTR-181, an opoid analgesic, met the primary and secondary endpoints in the SUMMIT-07 Phase 3 study. NKTR-181, Necktar's treatment for pain "without the high levels of euphoria that can lead to abuse and addiction with standard opioids," significantly improved chronic back pain relief compared to placebo, meeting the primary efficacy endpoint. Nektar said the trial also met key secondary endpoints with "high statistical significance." NKTR-181 also demonstrated a favorable safety profile and was well tolerated, Nektar said. The company said the Food and Drug Administration granted the investigational medicine Fast Track designation for the treatment of moderate to severe chronic pain. "The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study," said Martin Hale, the clinical investigator of the study and medical director at Gold Coast Research. POSITIVE OUTCOME 'SOMEWHAT OF A SURPRISE': TheStreet's Adam Feuerstein said the positive outcome of the Phase 3 study comes as "somewhat of a surprise" as the drug failed to beat the placebo in a previous Phase 2 study. Feuerstein noted that Nektar will not spend more money on NKTR-181, but said the Phase 3 study should strengthen its plan to outlicense the painkiller to a partner. If completed, Feuerstein said that a deal would create "a nice financial windfall" for the company. ANALYST 'HAPPY TO BE PROVEN WRONG': In a note to clients this morning, Piper Jaffray analyst Joshua Schimmer reiterated his Overweight rating on the stock and raised his price target to $29 from $25, and said that he is "happy to be proven wrong," as he believed prospects of success were very low following the failed Phase 2 study. Schimmer noted that Nektar is one of his top mid-cap biotech stocks for reasons including an emerging immuno-oncology platform and a value support provided by multiple royalty streams from partnered products. PRICE ACTION: Nektar Therapeutics is up about 27% in early trading to $19.64. Shares are up more than 60% year-to-date.

  • 29

    Mar

  • 01

    Apr

NKTR Nektar
$15.50

-0.21 (-1.34%)

03/20/17
PIPR
03/20/17
NO CHANGE
Target $29
PIPR
Overweight
Nektar price target raised to $29 after opioid trial success at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he thought prospects of success for NKTR-181 were very low after a failed Phase 2 study but he was "happy to be proven wrong" after the SUMMIT trial succeeded. A human abuse liability study will read-out around mid-2017, after which the company will meet with the FDA to discuss whether the package for NKTR-181 is adequate for filing, Schimmer noted. He raised his price target on Nektar shares to $29 from $25 and keeps an Overweight rating on the stock, which he calls his "top mid-cap biotech stocks for other reasons," such as its multiple royalty streams from partnered products and its emerging immuno-oncology platform.
01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.
01/06/17
BTIG
01/06/17
INITIATION
Target $22
BTIG
Buy
Nektar initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started Nektar Therapeutics with a Buy rating and $22 price target. Several "intriguing" emerging therapeutics along with multiple near-term catalysts make the shares attractive, Hazlett tells investors in a research note.
01/03/17
JANY
01/03/17
NO CHANGE
JANY
Janney sees pricing, rising rates as biotech headwinds in 2017
Janney Capital analyst Debjit Chattopadhyay noted that, on a relative basis vs. the Nasdaq, 2016 was the worst year for the Nasdaq biotechnology index (NBI) since 1994 and he believes the "outlook for 2017 isn't particularly rosy" given structural challenges for the sector along with rising interest rates. He cautions about overenthusiasm on M&A, as Chattopadhyay thinks "cash rich pharma may choose to return cash to shareholders through increased buybacks and dividends," and he believes "M&A, if any, is likely to lead to short-term relief rallies and may not represent a broader turn in sentiment." Meanwhile, broader discussion on healthcare spending and regulatory changes are likely to be bigger drivers of biotech sentiment during 2017 than M&A, said Chattopadhyay, who listed bluebird bio (BLUE), Galapagos NV (GLPG), Vertex (VRTX), Clovis (CLVS) and Nektar (NKTR) as on the firm's 2017 biotechnology focus list.

TODAY'S FREE FLY STORIES

CCN

CardConnect

$13.65

-0.25 (-1.80%)

, FDC

First Data

$16.64

-0.03 (-0.18%)

20:43
05/29/17
05/29
20:43
05/29/17
20:43
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

CCN

CardConnect

$13.65

-0.25 (-1.80%)

FDC

First Data

$16.64

-0.03 (-0.18%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

PPG

PPG

$107.24

0.33 (0.31%)

GM

General Motors

$33.07

0.47 (1.44%)

DIS

Disney

$108.41

1.14 (1.06%)

VIA

Viacom

VIAB

Viacom

$35.13

0.21 (0.60%)

F

Ford

$10.93

0.07 (0.64%)

IP

International Paper

$52.42

0.26 (0.50%)

CROX

Crocs

$6.59

0.12 (1.85%)

YHOO

Yahoo

$50.67

0.07 (0.14%)

FL

Foot Locker

$59.82

0.16 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 01

    Jun

  • 06

    Jun

  • 08

    Jun

  • 12

    Jun

  • 15

    Jun

  • 27

    Jul

  • 25

    Oct

AMGP

Antero Midstream GP

$21.97

-0.09 (-0.41%)

20:34
05/29/17
05/29
20:34
05/29/17
20:34
Initiation
Antero Midstream GP initiated  »

Antero Midstream GP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AM

Antero Midstream

$34.28

-0.06 (-0.17%)

20:32
05/29/17
05/29
20:32
05/29/17
20:32
Initiation
Antero Midstream initiated  »

Antero Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLP

Archrock Partners LP

20:30
05/29/17
05/29
20:30
05/29/17
20:30
Downgrade
Archrock Partners LP rating change  »

Archrock Partners LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGP

Antero Midstream

$21.97

-0.09 (-0.41%)

20:28
05/29/17
05/29
20:28
05/29/17
20:28
Initiation
Antero Midstream initiated  »

Antero Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXY

Occidental Petroleum

$61.00

0.29 (0.48%)

20:27
05/29/17
05/29
20:27
05/29/17
20:27
Initiation
Occidental Petroleum initiated  »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRO

Frontline

$5.63

-0.39 (-6.48%)

, AMWD

American Woodmark

$88.90

1.3 (1.48%)

20:25
05/29/17
05/29
20:25
05/29/17
20:25
Earnings
Notable companies reporting before Tuesday's open »

Notable companies…

FRO

Frontline

$5.63

-0.39 (-6.48%)

AMWD

American Woodmark

$88.90

1.3 (1.48%)

SFL

Ship Finance

$13.05

-0.25 (-1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

WDC

Western Digital

$90.01

0.74 (0.83%)

, TOSBF

Toshiba, also use TOSYY

$2.30

0.0023 (0.10%)

20:04
05/29/17
05/29
20:04
05/29/17
20:04
Periodicals
INCJ considers joint bid with Western Digital for Toshiba chips, Nikkei says »

State-backed Innovation…

WDC

Western Digital

$90.01

0.74 (0.83%)

TOSBF

Toshiba, also use TOSYY

$2.30

0.0023 (0.10%)

TOSYY

Toshiba, also use TOSBF

$13.80

-0.1 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$971.47

1.93 (0.20%)

, GOOGL

Alphabet Class A

$993.27

1.41 (0.14%)

20:01
05/29/17
05/29
20:01
05/29/17
20:01
Periodicals
Google, Sharp partner on VR displays, Nikkei says »

Google (GOOG) and…

GOOG

Alphabet

$971.47

1.93 (0.20%)

GOOGL

Alphabet Class A

$993.27

1.41 (0.14%)

HNHPF

Hon Hai Precision

SHCAY

Sharp

$3.80

0.1 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 28

    Jun

  • 19

    Jul

MU

Micron

$29.76

0.33 (1.12%)

19:58
05/29/17
05/29
19:58
05/29/17
19:58
Periodicals
Micron to invest $2B in Japan memory chip facility, Nikkei says »

Micron plans to invest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 06

    Jun

  • 07

    Jun

  • 09

    Jun

  • 15

    Jun

LNEGY

Linde

$19.28

-0.09 (-0.46%)

19:56
05/29/17
05/29
19:56
05/29/17
19:56
Periodicals
Linde to receive 'major' order from Russian company, Reuters says »

Linde is set to receive a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$16.64

-0.03 (-0.18%)

, CCN

CardConnect

$13.65

-0.25 (-1.80%)

19:38
05/29/17
05/29
19:38
05/29/17
19:38
Hot Stocks
First Data to acquire CardConnect for $15.00 per share »

First Data (FDC) and…

FDC

First Data

$16.64

-0.03 (-0.18%)

CCN

CardConnect

$13.65

-0.25 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

SSNLF

Samsung

$2,000.00

200 (11.11%)

, LYV

Live Nation

$34.25

0.05 (0.15%)

19:33
05/29/17
05/29
19:33
05/29/17
19:33
Hot Stocks
Samsung announces 'VR Live Pass,' new virtual reality partnerships »

Samsung (SSNLF) announced…

SSNLF

Samsung

$2,000.00

200 (11.11%)

LYV

Live Nation

$34.25

0.05 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

FISV

Fiserv

$124.09

-0.43 (-0.35%)

19:31
05/29/17
05/29
19:31
05/29/17
19:31
Hot Stocks
Fiserv says selected by Bank of Sydney »

Fiserv announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$37.55

1.6 (4.45%)

19:29
05/29/17
05/29
19:29
05/29/17
19:29
Periodicals
Nintendo orders production ramp for 'Switch' console, FT reports »

Nintendo has ordered a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$325.14

8.31 (2.62%)

, CSIQ

Canadian Solar

$13.24

-0.48 (-3.50%)

19:16
05/29/17
05/29
19:16
05/29/17
19:16
Hot Stocks
WTO says U.S. launches investigation into solar cell imports »

The World Trade…

TSLA

Tesla

$325.14

8.31 (2.62%)

CSIQ

Canadian Solar

$13.24

-0.48 (-3.50%)

FSLR

First Solar

$36.84

-1.1 (-2.90%)

JASO

JA Solar

$6.91

-0.28 (-3.89%)

SPWR

SunPower

$7.95

-0.28 (-3.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 06

    Jun

  • 20

    Jun

  • 29

    Jun

  • 02

    Oct

LRLCY

L'Oreal

$42.24

-0.165 (-0.39%)

18:47
05/29/17
05/29
18:47
05/29/17
18:47
Periodicals
Renhe Pharmacy mulls joining auction for The Body Shop, Sky News says »

China's Renhe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$153.61

-0.26 (-0.17%)

, QCOM

Qualcomm

$57.52

-0.93 (-1.59%)

18:43
05/29/17
05/29
18:43
05/29/17
18:43
Periodicals
Apple hires former Qualcomm VP to head SoC efforts, AppleInsider says »

Apple (AAPL) has hired…

AAPL

Apple

$153.61

-0.26 (-0.17%)

QCOM

Qualcomm

$57.52

-0.93 (-1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

GS

Goldman Sachs

$223.53

1.06 (0.48%)

18:40
05/29/17
05/29
18:40
05/29/17
18:40
Periodicals
Goldman Sachs bought $2.8B in Venezuelan bonds, WSJ says »

Goldman Sachs purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 18

    Jul

  • 17

    Oct

ICAGY

IAG

$15.65

-0.305 (-1.91%)

18:36
05/29/17
05/29
18:36
05/29/17
18:36
Hot Stocks
British Airways suffers 'major' IT failure »

IAG's British…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$77.01

-0.47 (-0.61%)

18:20
05/29/17
05/29
18:20
05/29/17
18:20
Hot Stocks
Canadian National reaches tentative labor with train conductors, yard employees »

CN announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$107.24

0.33 (0.31%)

, AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

16:29
05/29/17
05/29
16:29
05/29/17
16:29
Hot Stocks
PPG says remains willing to engage with AkzoNobel »

PPG (PPG) issued the…

PPG

PPG

$107.24

0.33 (0.31%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$107.24

0.33 (0.31%)

, AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

16:27
05/29/17
05/29
16:27
05/29/17
16:27
Periodicals
Court rejects Elliott challenge against AkzoNobel, Bloomberg says »

The Dutch Commercial…

PPG

PPG

$107.24

0.33 (0.31%)

AKZOY

AkzoNobel

$28.37

-0.11 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$108.41

1.14 (1.06%)

, VIA

Viacom

16:21
05/29/17
05/29
16:21
05/29/17
16:21
Hot Stocks
Box Office Battle: 'Pirates' wins holiday weekend as 'Baywatch' stumbles »

Disney's (DIS)…

DIS

Disney

$108.41

1.14 (1.06%)

VIA

Viacom

VIAB

Viacom

$35.13

0.21 (0.60%)

FOX

21st Century Fox

$26.95

-0.28 (-1.03%)

FOXA

21st Century Fox

$27.03

-0.3 (-1.10%)

TWX

Time Warner

$99.07

0.1025 (0.10%)

CMCSA

Comcast

$40.91

0.57 (1.41%)

CMCSK

Comcast

LGF.A

Lionsgate

$27.76

2.21 (8.65%)

LGF.B

Lionsgate

$25.56

2.11 (9.00%)

SNE

Sony

$36.68

0.51 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

  • 12

    Jun

  • 15

    Jun

  • 15

    Jun

  • 27

    Jun

DGAS

Delta Natural Gas

15:56
05/29/17
05/29
15:56
05/29/17
15:56
Conference/Events
Delta Natural Gas to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.